BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
25 janv. 2024 01h00 HE
|
BioSenic
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une...
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
25 janv. 2024 01h00 HE
|
BioSenic
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
Viscosupplementation Market Global Analysis and Forecast 2031 - Market Forecast to Surge in Valuation by 2031 with Single Injection Segment Leading Growth in North America and Asia Pacific Regions
28 déc. 2023 05h28 HE
|
Research and Markets
Dublin, Dec. 28, 2023 (GLOBE NEWSWIRE) -- The "Viscosupplementation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application,...
Orthopedic Pain Management and Joint Reconstruction Lead Applications in the Expanding Orthopedic Regenerative Surgical Products Market
23 oct. 2023 07h33 HE
|
Research and Markets
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report By Product (Allografts, Viscosupplements), By End-use...
Global Viscosupplementation Markets Report 2022: A $8.958 Billion Market by 2030 from $4 Billion in 2021 - Surging Geriatric Populations and Prevalence of Osteoarthritis will Drive Market Growth
27 févr. 2023 10h28 HE
|
Research and Markets
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Viscosupplementation Market, By Product Type, By End User, Estimation & Forecast, 2017-2030" report has been added to ...
Insights on the Orthopedic Regenerative Surgical Products Global Market to 2030 - Featuring Baxter, Zimmer Biomet and Allosource Among Others
21 avr. 2022 06h48 HE
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic, Cell-based,...
Bone Therapeutics annonce les résultats principaux de l'étude de Phase III évaluant son viscosupplément amélioré, le JTA-004, dans l'arthrose du genou
30 août 2021 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Aucune différence statistiquement significative n’a été observée dans la réduction de la douleur du genou entre JTA-004, le placebo et le comparateur actif 3 mois après le...
Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
30 août 2021 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
19 juil. 2021 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Bone Therapeutics provides update on the progress of clinical studies
19 juil. 2021 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...